The Global Retinal Pharmaceuticals Market 2019-2024 Renders deep perception of the Market Segment by Regions, market status of the Retinal Pharmaceuticals on a global level that primarily aims the core...
The "Global Ophthalmology Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on March 8th, 2019 at $403.55. In approximately 2 month, Regeneron Pharm has returned 17.23% as of today's recent price of $334.03.
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $350.50 to a high of $363.09. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of...
Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $385.86 to a high of $389.43. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of...
We take a look at companies, which have been developing treatments for various diseases using RNAi technology.
Key highlights of the past week are new drug approvals, collaborations and pipeline updates.
Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2019 financial and operating results on Tuesday, May 7, 2019, before the U.S. financial markets open....
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $396.74 to a high of $400.89. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of...
--a^' Regeneron to Invest $800 million Through Upfront Cash and Equity Investment in Alnylam, with up to Additional $200 Million in Potential Near-Term Milestones -
Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases
The "Cat Allergy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $409.32 to a high of $414.84. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.